Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks. In this case, Corvus is initiating an early-stage study in patients with COVID-19.
Specifically, Corvus has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. This comes after the U.S. Food and Drug Administration’s (FDA) review and acceptance of the firm’s investigational new drug (IND) application for the COVID-19 study.
Corvus is studying an agonistic (immunostimulatory) humanized monoclonal antibody, CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.
In both in vitro and in vivo studies in cancer patients, CPI-006 has demonstrated binding to various immune cells and the inducement of a humoral adaptive immune response: B cell activation and lymphocyte trafficking leading to the production of antigen-specific immunoglobulin (IgM and IgG) antibodies. In simpler terms, CPI-006 has been proven to produce an immune response.
Corvus has had some success with CPI-006 in the past with a couple of cancer studies. In these studies, CPI-006 was well tolerated and was able to produce an immune response.
The potential as an immunotherapy treatment for COVID-19 could be tremendous. Although this is only an early-stage study, it is very possible that the FDA would fast track this if the results are strong.
Excluding Tuesday’s move, Corvus Pharmaceuticals stock had underperformed the broad markets, with a retreat of about 50% year to date. However, over the past quarter, the stock was actually up about 36%.
The shares traded up about 120% on Tuesday, at $6.03 in a 52-week range of $1.01 to $6.43. The consensus price target is $8.60.
24/7 Wall St.Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
